Content about Santarus

January 3, 2014

Salix Pharmaceuticals has completed its $2.6 billion acquisition of Santarus, Salix said.

RALEIGH, N.C. — Salix Pharmaceuticals has completed its $2.6 billion acquisition of Santarus, Salix said.

The drug maker announced that it had completed the $32-per-share acquisition of Santarus, which the companies announced in November. The combination of the companies' product portfolios includes 22 marketed products, such as Xifaxan, Glumetza, Zegerid, Relistor and others.

November 8, 2013

Salix Pharmaceuticals will buy Santarus for $2.6 billion, the drug makers said.

RALEIGH, N.C. — Salix Pharmaceuticals will buy Santarus for $2.6 billion, the drug makers said.

Salix will acquire all outstanding common stock of Santarus for $32 in cash, representing an approximately 36% premium over the Wednesday closing price of the company. The acquisition is expected to close in first quarter 2014. Both companies specialize in gastrointestinal drugs.

January 16, 2013

The Food and Drug Administration has approved an ulcerative colitis drug made by Santarus, the drug maker said.

SAN DIEGO — The Food and Drug Administration has approved an ulcerative colitis drug made by Santarus, the drug maker said.

Santarus announced the approval of Uceris (budesonide) extended-release tablets for mild to active UC. The company plans to launch the drug in March.